LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. 2. Juni 2012 Schimanski, C.C., Mohler, M., Schon, M., van Cutsem, E., Greil, R., Bechstein, W.O., Hegewisch-Becker, S., von Wichert, G., Vohringer, M., Heike, M., Heinemann, V., Peeters, M., Kanzler, S., Kasper, S., Overkamp, F., Samonigg, H., Seehofer, D., Kullmann, F., Schmidtmann, I., Smith-Machnow, V., Gockel, I., Lang, H., Galle, P.R., 2012. BMC Cancer 12, 144. doi:10.1186/1471-2407-12-144 Abstract A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. Schimanski, C.C., Moehler, M.H., Lang, H., Schoen, M., Smith-Machnow, V., Kanzler, S., Hegewisch-Becker, S., Doerfel, S., Seehofer, D., Bechstein, W., Heike, M., Overkamp, F., Kullmann,… Weiterlesen Mutation analysis from the REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. Schirmacher, P., Schuette, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Zaun, S., Dietel, M., 2012. Weiterlesen